You are here

Grant Process

Pfizer is continuously striving to improve its process with the goal of ensuring regulatory compliance while providing independent grants to support initiatives that accelerate the translation of clinical science into quality patient care.


Track 1 – Healthcare Quality Improvement & Education

The strategic global priorities for Healthcare Quality Improvement & Education for the current year are:

  • Rare Disease
  • Inflammation
  • Pain
  • Vaccines

RFPs will be posted on our website. In addition, they will also be disseminated through e-mail to all registered organizations. IGLC expects to release 2-3 RFPs per clinical area per year. Please visit the Request for Proposals section of this site for details regarding open RFPs.

Track 2 – Knowledge Gap

Knowledge Gap grants will focus on educational strategies specially designed to close gaps in knowledge and improve competence in certain clinical areas, as identified through needs assessment and other data that would support this type of strategy. Types of funding currently available include:

  • Annual Meeting Support: Eligible organizations can request funding to support LIVE national and regional conferences and congresses. CLICK HERE to view the 2018 clinical areas of interest and goals as well as submission deadlines.
  • Visiting Professorship Support: Eligible organizations can request funding to host a Distinguished Medical Expert to foster educational exchanges with local healthcare providers in a similar or allied area to those listed, who can benefit from the Expert's knowledge and on-site presence. CLICK HERE to view the 2018 areas of interest, application requirements and submission deadlines.
  • Call for Grant Applications (CGA): In certain clinical areas, a Call for Grant Applications (CGA) will also be posted. The CGA will describe (1) the clinical area of interest, (2) the approximate total budget available, (3) the rationale behind the need for knowledge-driven education or assessment, (4) the outcome-reporting required, and (5) what information must be in the application.  To view previously posted CGAs that are now closed (i.e., applications no longer accepted) please click here.
    • Currently open CGAs:
    CGA ID # Geographic Scope Issue Date CGA Submission Deadline



    December 1, 2017

    Anti-Tissue Factor Pathway Inhibitor Approaches in Hemophilia Treatment: Supporting Local and Regional Activities

    September 30, 2018


    APAC Region: Australia, India, Indonesia, Malaysia, New Zealand, Pakistan, Philippines, Singapore, South Korea, Thailand, and Vietnam 

    January 29, 2018

    Asia Pacific (APAC) Local Community Grants 

    October 1, 2018

    CGA18RA1 International: All European countries (including Israel, Turkey and Russia) April 3, 2018 Rheumatoid arthritis preceptorship programme

    June 30, 2018 (extended to September 20, 2018)

    CGA18AI2 Global  July 30, 2018 Global Antimicrobial Stewardship September 20, 2018
    CGA18PA1  US only  September 4, 2018 Advances in the Future of Chronic Pain Management  September 30, 2018

 Clinical Areas Reviewed through Joint Alliances/Partnerships

Please note, in order to apply to any of the Joint Alliance/Partnership programs listed below your organization must also meet Pfizer’s eligibility requirements. Click here to view further details about eligibility.

  • Chronic Pain Associated with Osteoarthritis and Chronic Low Back Pain

    Pfizer and Lilly are working together on grants in support of medical education in chronic pain associated with osteoarthritis and chronic low back pain. We are committed to supporting innovative, independent medical education for healthcare professionals.

    All grant applications should be submitted to Pfizer only, to avoid application duplication. To apply now, go to our grant management system.

  • Diabetes Treatment 

    Pfizer and Merck are working together on grants in support of diabetes treatment-related education. The goal of this education is to increase the understanding of SGLT2 inhibition in the management of diabetes.

    All grant applications should be submitted to Merck only. Please refer to the Merck website for information.

  • Nonsteroidal Anti-Androgen Treatment of Prostate & Breast Cancer

    Pfizer and Astellas are working together on grants in support of prostate cancer-related education. The goal of this education is to increase the ability of healthcare professionals to consistently provide their patients with optimal guidelines-based care.

    Pfizer and Astellas are also invested in advancing the understanding of nonsteroidal anti-androgens in the treatment of breast cancer.

    All grant applications should be submitted to Astellas only. Please refer to the Astellas website for information.

  • Thrombosis Prevention / Anti-coagulation

    Pfizer and Bristol Myers Squibb (BMS) are working together on grants in support of thrombosis / anticoagulation-related education. The goal of this education is to decrease the unmet medical needs in the prevention and treatment of venous and arterial thrombosis.

    All grant applications should be submitted to Bristol Myers Squibb only. Please refer to the Bristol Myers Squibb website for information.


Organizations Eligible to Receive Grants and Process Overview

Pfizer is committed to supporting healthcare quality improvement initiatives, continuing professional development and other independent education activities, including CME/CE, that are most likely to improve patient health, and believe that the likelihood of improving patient health increases when education is integrated with quality. We believe commercial support should be aligned with the literature on effective continuing education for health professionals, and the highest level of standards endorsed by the medical community such as those found in the 2006 ACCME criteria.

Types of organizations eligible to apply for grants include hospitals, academic medical centers, schools of nursing or pharmacy, professional societies and associations, and other entities with a mission related to healthcare professional education and/or healthcare improvement.View further details about eligibility.

View the full description of the grant application process.



Throughout the year Independent Grants for Learning & Change (IGLC) may send out communications directly to registered users of the Pfizer Grant Management System (GMS) with regard to important and time-sensitive topics (e.g., change in policy, changes in process or procedures, system enhancements). Such communications are posted below for your reference in descending chronological order. In addition to announcements prepared by IGLC, posted below you will find other relevant information we wish to share with our stakeholder community.


Date Posted Description Link
01/31/16 IGLC Sunshine FAQ - updated Jan 2016
02/28/15 IGLC Sunshine FAQ - updated Feb 2015
10/02/13 Press Release: International Atherosclerosis Society And Pfizer Independent Grants For Learning & Change Collaborate On New Grant Opportunity
08/30/13 Sunshine FAQ following IGLC webinar
08/01/13 Sunshine Act: Final Regulations and Implications for our Independent Grants Program
04/08/13 Pfizer IGLC announces new name
01/02/13 NEW online Grant Management System
09/13/12 Women's Health Platform
02/07/12 FAQ about new model
01/03/12 Pfizer MEG announces new model
12/27/11 Seeking nominations for External Review Panel Members
03/25/11 Pfizer Medical Education Group — King integration
11/04/09 Pfizer's support of ACCME Transparency Statement
10/20/09 Pfizer Medical Education Group – integration
12/03/08 Change in Pfizer's CME Grant Policy pursuant to state Attorneys General settlement-CME faculty with promotional speaking involvement
9/15/08 Pfizer's response to ACCME Call for Comments
7/18/08 Statement on Pfizer's recent policy change re CME support
7/18/08 FAQs re Pfizer's recent policy change re CME support
7/02/08 Pfizer announces policy change re CME support


File Description

Approved Full Proposal Final Report Overview

Upon completion of a project funded through a Request for Proposal (RFP), grant recipients will be asked to complete a "Full Proposal Final Report". This is a copy of the final report questions that will be asked.

Approved Full Proposal Interim Report Overview


Throughout the lifecycle of a project funded through a Request for Proposal (RFP), grant recipients will be asked to complete a "Full Proposal Interim Report". This is a copy of the interim report questions that will be asked.

Request for Scope Change

If a request for a timeline extension/scope change is received by Pfizer, a report will be assigned to the Grant Requestor in the Grant Management System. This is a copy of the questions that will be asked. 

Project Classification Decision Matrix

There are multiple project types that are eligible for funding through an IGLC RFP. When submitting for funding, organizations will be asked to indicate which of the following best represents their project.

  • Dissemination and Implementation (D&I) Research
  • Quality Improvement  Education
  • Educational research

This file provides more information on these classifications.

RFP - Terms & Conditions

Every Request for Proposal (RFP) released by Pfizer Independent Grants for Learning & Change (IGLC), as well as a RFP released jointly with a Partner(s), is governed by specific terms and conditions. This is a copy of the terms and conditions.

CGA - Terms & Conditions

Every Call for Grant Application (CGA) released by Pfizer Independent Grants for Learning & Change (IGLC) isgoverned by specific terms and conditions. This is a copy of the terms and conditions.